Carlo Z.
- Country
- Belgium
- Department
- Cardiology
Research Overview
- Evaluation of Aspirin Omission on Bleeding and Ischemic Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome Patients
- Phase 3 Randomized Study Comparing Asundexian and Apixaban for Stroke Prevention in Atrial Fibrillation Patients at Risk
- Evaluation of Inclisiran's Efficacy in Reducing Major Adverse Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 136 of 655 partner sites.
Specializations
Cardiovascular Disease Management
Specializes in treating patients with atherosclerotic cardiovascular disease (ASCVD), focusing on innovative approaches to reduce cardiovascular events and improve patient outcomes.
- Lipid Management
- Cardiovascular Risk Reduction
- Prevention of Major Adverse Cardiovascular Events
Investigates therapeutic interventions for patients with elevated LDL cholesterol levels and established vascular disease.
Acute Coronary Syndromes
Focuses on optimizing treatment strategies for patients with non-ST-segment elevation acute coronary syndrome, with particular attention to antithrombotic therapy approaches.
- Bleeding Risk Management
- Antiplatelet Therapy
- Ischemic Event Prevention
Explores alternative therapeutic strategies to enhance safety while maintaining efficacy in acute coronary care.
Stroke Prevention
Dedicated to advancing treatment options for stroke prevention in atrial fibrillation, with expertise in evaluating novel anticoagulation approaches.
- Atrial Fibrillation Management
- Systemic Embolism Prevention
- Bleeding Risk Assessment
Evaluates innovative therapeutic agents for stroke prevention while optimizing safety profiles in cardiac patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
